Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria

• Vertex reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease across two patient cohorts.
• Treatment reduced protein in urine in patients with modest proteinuria, supporting potential use beyond the earlier focal segmental glomerulosclerosis population.
• Patients with type 2 diabetes saw a smaller improvement, suggesting a more variable response in that subgroup.
• Safety profile was generally favorable, with no drug-related serious adverse events reported.
• Enrollment finished in the Phase 2/3 AMPLITUDE trial, with interim results expected in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921995768) on September 22, 2026, and is solely responsible for the information contained therein.